Back to search
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Hematological Malignancies
Clinicaltrials.gov:
EU CTIS:
#2023-504581-29-00
EudraCT:
J&J ID:
#CR108920
Other:
#TALMMY1001-PT3
Interested in this trial?
Subscribe or share this trial
Trials at a glance
Status
Enrolling
Condition
Hematological Malignancies
Trial type
Interventional
Trial phase
Phase 2
Investigational
product
product
Talquetamab
Age
18+ years old
Biological sex
All
Placebo?
No
Trial start date
February 1, 2021
Trial end date
March 30, 2029
CT.gov ID
#NCT04634552
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
Countries:
- Belgium,
- China,
- France,
- Germany,
- Israel,
- Japan,
- Netherlands,
- Poland,
- South Korea,
- Spain,
- United States
Loading...
Enrolling
Pamplona, Spain, 31008
Enrolling
Atlanta, Georgia, United States, 30322
Enrolling
Salamanca, Spain, 37007
Enrolling
Barcelona, Spain, 08035
Enrolling
Santander, Spain, 39008
Enrolling
Seville, Spain, 41013
Enrolling
Hollywood, Florida, United States, 33021
Enrolling
New York, New York, United States, 10023
Enrolling
Louisville, Kentucky, United States, 40207
Enrolling
Birmingham, Alabama, United States, 35294
Enrolling
Little Rock, Arkansas, United States, 72205
Enrolling
Chicago, Illinois, United States, 60637
Enrolling
Ann Arbor, Michigan, United States, 48109
Enrolling
Rochester, New York, United States, 14642
Enrolling
St Louis, Missouri, United States, 63110
Enrollment complete
Nantes, France, 44093
Enrollment complete
Créteil, France, 94000
Enrollment complete
Pessac, France, 33604
Enrollment complete
Liège, Belgium, 4000
Enrollment complete
Montpellier, France, 34295
Enrollment complete
Haifa, Israel, 3436212
Enrollment complete
Berlin, Germany, 12203
Enrollment complete
Koshigaya, Japan, 343-8555
Enrollment complete
Suzhou, China, 215006
Enrollment complete
Fukuoka, Japan, 814-0180
Enrollment complete
Jerusalem, Israel, 91120
Enrollment complete
Pozuelo de Alarcón, Spain, 28223
Enrollment complete
Madrid, Spain, 28041
Enrollment complete
Murcia, Spain, 30120
Enrollment complete
Lyon, France, 69002
Enrollment complete
Barcelona, Spain, 8908
Enrollment complete
Tianjin, China, 300320
Enrollment complete
Shiwa-gun, Japan, 028-3695
Enrollment complete
Osaka, Japan, 543 8555
Enrollment complete
Chiba, Japan, 296-8602
Enrollment complete
Kobe, Japan, 650 0047
Enrollment complete
Kumamoto, Japan, 860-8556
Enrollment complete
Kurashiki, Japan, 710-8602
Enrollment complete
New York, New York, United States, 10016
Enrollment complete
Ōtake, Japan, 739-0696
Enrollment complete
Matsumoto, Japan, 399-8701
Enrollment complete
Okayama, Japan, 701-1192
Enrollment complete
Gifu, Japan, 503-8502
Enrollment complete
Beijing, China, 100191
Enrollment complete
Toulouse, France, 31059
Enrollment complete
Haifa, Israel, 31096
Enrollment complete
Ramat Gan, Israel, 52621
Enrollment complete
Guangzhou, China, 510060
Enrollment complete
Tel Aviv, Israel, 64239
Enrollment complete
Hangzhou, China, 310003
Enrollment complete
Hangzhou, China, 310003
Enrollment complete
Xi'an, China, 710063
Enrollment complete
Leuven, Belgium, 3000
Enrollment complete
Heidelberg, Germany, 69120
Enrollment complete
Würzburg, Germany, 97080
Enrollment complete
Wroclaw, Poland, 50 367
Enrollment complete
Poznan, Poland, 60-569
Enrollment complete
Gdansk, Poland, 80 214
Completed
Seoul, South Korea, 05505
Completed
Jeollanam-do, South Korea, 58128
Completed
Duarte, California, United States, 91010
Completed
Madrid, Spain, 28040
Completed
Badalona, Spain, 08916
Completed
Warsaw, Poland, 02-781
Completed
Gliwice, Poland, 44102
Completed
Portland, Oregon, United States, 97213
Completed
Seoul, South Korea, 06351
Completed
Seoul, South Korea, 03080
Completed
Seoul, South Korea, 03722
Completed
Hokkaido, Japan, 006-8555
Completed
Nashville, Tennessee, United States, 37203
Completed
Seoul, South Korea, 06591
Completed
Xi'an, China, 710004
Completed
Woluwe-Saint-Lambert, Belgium, 1200
Completed
Utrecht, Netherlands, 3584 CX
Completed
Edegem, Belgium, 2650
Completed
Münster, Germany, 48149
Completed
Amsterdam, Netherlands, 1081 HV
#
More than 50 sites in this region
#
More than 10 sites in this region
#
Less than 10 sites in this region
Individual sites
Access detailed information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2026
